banoxantrone
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2004 (NCT00090727)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DNA topoisomerase IIINHIBITOR
DNA topoisomerase II inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2c1C(=O)c1c(O)ccc(O)c1C2=O- Mol. weight
- 444.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL117391 ↗
Also known as
- 1,4-bis-((2-(dimethylamino)ethyl)amino)-5,8-dihydroxyanthracene-9,10-dione
- 1,4-bis-((2-(dimethylamino-n-oxide)ethyl)amino)-5,8-dihydroxyanthracene-9,10-dione
- aq4n
- aq4n
- aq4n
- banoxantrone
- banoxantrone
- banoxantrone
- banoxantrone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00394628 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2006 | Novacea |
| NCT00109356 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2005 | Novacea |
| NCT00090727 | Phase 1 | Aug 1, 2004 | Novacea |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novacea | For profit | 3 | 3 | 2 | 2004 |
1 organizations
Page 1 / 1